Injection site reaction to adalimumab: Positive skin test and successful rapid desensitisation.
S
S
Bavbek
Ş
Ş
Ataman
L
L
Bankova
M
M
Castells
D000068879:Adalimumab; D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D003888:Desensitization, Immunologic / Q000379:methods; D004155:Diphenhydramine / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D003875:Drug Eruptions / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology* / Q000628:therapy; D004890:Erythema / Q000139:chemically induced*; D015738:Famotidine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D007428:Intradermal Tests; D011537:Pruritus / Q000139:chemically induced*; D012882:Skin Tests; D013997:Time Factors
D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D015738:Famotidine; D004155:Diphenhydramine; D000068879:Adalimumab